In Vitro Activity of Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring Antimicrobial Resistance Trends (SMART), 2015-2018.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Considering the increasing incidence of carbapenem-resistant Enterobacteriaceae in China, this study aimed to establish the in vitro effectiveness of imipenem/relebactam (IMI/REL) on clinical Enterobacteriaceae isolates derived from intra-abdominal infections (IAIs), respiratory tract infections (RTIs), and urinary tract infections (UTIs) in China between 2015 and 2018.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Infect Dis

Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1537-6591

ISSN (Print): 1058-4838

Publication date (Electronic): December 23 2020

Volume: 71

Issue: Suppl 4

Affiliations

[1 ] Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.

[2 ] Department of Infectious Diseases, Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, Hangzhou, China.

[3 ] Department of Microbiology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.

[4 ] Microbiology Laboratory, Jilin Province People's Hospital, Changchun, China.

[5 ] Department of Laboratory Medicine, Shandong Provincial Hospital affiliated with Shandong University, Jinan, China.

[6 ] Division of Microbiology, Haikou People's Hospital, Haikou, China.

[7 ] Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

[8 ] Division of Microbiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

[9 ] Microbiology Laboratory, Beijing Chao-yang Hospital, Beijing, China.

[10 ] Department of Microbiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.

[11 ] Infection Control Center, Xiangya Hospital, Central South University, Changsha, China.

[12 ] Department of Infectious Diseases, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

[13 ] Division of Microbiology, No. 1 Affiliated Hospital of Kunming Medical University, Kunming, China.

[14 ] Division of Microbiology, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China.

[15 ] Division of Microbiology, Shanghai Huashan Hospital, Shanghai, China.

[16 ] Division of Microbiology, Sichuan Province People's Hospital, Chengdu, China.

[17 ] MRL Global Medical Affairs, MSD China, Shanghai, China.

Article

Publisher Item ID: 6046212

DOI: 10.1093/cid/ciaa1519

PubMed ID: 33367580

SO-VID: b31a0a8a-38fe-4247-83fe-3715258662d4

History

Keywords: Enterobacteriaceae,SMART,carbapenem,imipenem-nonsusceptible,imipenem/relebactam

Data availability:

Keywords: Enterobacteriaceae, SMART, carbapenem, imipenem-nonsusceptible, imipenem/relebactam

In Vitro Activity of Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring Antimicrobial Resistance Trends (SMART), 2015-2018.

Read this article at

Abstract

Related collections

Fandom activity

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 202

Cited by 6